American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004. Journal Of Clinical Oncology 2004, 23: 619-629. PMID: 15545664, DOI: 10.1200/jco.2005.09.121.Peer-Reviewed Original ResearchConceptsReceptor-positive breast cancerHormone receptor-positive breast cancerClinical Oncology technology assessmentAromatase inhibitor therapyPostmenopausal womenAromatase inhibitorsBreast cancerEndocrine therapyAdjuvant therapyInhibitor therapyMultiple large randomized trialsOptimal adjuvant hormonal therapyHormone receptor-negative tumorsOptimal endocrine therapyTreatment-related amenorrheaAdjuvant endocrine therapyAdjuvant hormonal therapyLarge randomized trialsReceptor-negative tumorsSide effect profileUse of tamoxifenAromatase inhibitor treatmentAmerican SocietyAdjuvant settingInitial therapy